Quest Laborato.

Why is Quest Laboratories Ltd falling/rising?

As of 01-Sep, Quest Laboratories Ltd's stock price is Rs 85.65, reflecting a decline of 1.78%. The stock has underperformed significantly year-to-date and over the past year, with a notable drop in investor participation and trading levels below key moving averages.

As of 01-Sep, Quest Laboratories Ltd's stock price is falling, currently at Rs 85.65, which reflects a decrease of Rs 1.55 or 1.78%. This decline is supported by several factors outlined in the recent performance data. Over the past week, the stock has underperformed, showing a decrease of 0.98%, while the benchmark Sensex fell by 1.15%. In the last month, the stock has dropped by 4.03%, compared to a 1.34% decline in the Sensex.<BR><BR>Year-to-date, Quest Laboratories has experienced a significant decline of 22.21%, which is notably worse than the Sensex's 7.94% drop. Over the past year, the stock has generated a return of -13.92%, while the broader market has only seen a 2.31% decline. This underperformance is further highlighted by the stock's current trading levels, which are lower than all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day).<BR><BR>Additionally, there has been a marked decrease in investor participation, with delivery volume falling by 91.03% compared to the 5-day average. The stock is also close to its 52-week low, just 1.93% away from Rs 84. Despite some positive factors, such as high management efficiency and increasing institutional investor participation, the overall sentiment remains negative due to flat quarterly results and below-par performance in both the near and long term.

Which are the latest news on Quest Laborato.?

What does Quest Laborato. do?

Quest Laboratories Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 32 Cr and a net profit of 3 Cr for March 2026. It was incorporated in 1998 and became a public limited company in January 2024.

Overview: <BR>Quest Laboratories Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was originally incorporated in 1998 under the name "Quest Laboratories Private Limited." It later changed its status to Public Limited and adopted the name "Quest Laboratories Limited" in January 2024. The most recent quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>- Net Sales: 32 Cr (Quarterly Results - Mar 2026) <BR>- Net Profit: 3 Cr (Quarterly Results - Mar 2026) <BR>- Market Cap: INR 144 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 10.00 <BR>- Industry P/E: 37 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -0.19 <BR>- Return on Equity: 16.70% <BR>- Price to Book: 1.60 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Quest Laborato.?

Quest Laborato.'s peers include Bal Pharma, Auro Labs, Parnax Lab, and others, with varying management and growth risks. Parnax Lab leads in 1-year returns, while Quest Laborato. has a return of -11.65%.

Peers: The peers of Quest Laborato. are Bal Pharma, Auro Labs., Parnax Lab, Panch.Organics, Smruthi Organic, Kimia Bioscien., Achyut Healthcar, Syschem (India), and Lactose (India).<BR><BR>Quality Snapshot: Excellent management risk is observed at Quest Laborato. and Parnax Lab, while Average management risk is found at Bal Pharma, Auro Labs., Panch.Organics, Smruthi Organic, and the rest. Below Average management risk is noted for Kimia Bioscien., Achyut Healthcar, Syschem (India), and Lactose (India). In terms of Growth, Quest Laborato. shows Good growth, while Parnax Lab demonstrates Good growth as well. Average growth is seen at Achyut Healthcar, while Below Average growth is found at Bal Pharma, Auro Labs., Panch.Organics, Smruthi Organic, Kimia Bioscien., and the rest. Quest Laborato. has an Excellent capital structure, alongside Parnax Lab and Panch.Organics, while Good capital structure is noted for Smruthi Organic and Achyut Healthcar, and Below Average capital structure is observed at Bal Pharma, Auro Labs., Kimia Bioscien., Syschem (India), and Lactose (India).<BR><BR>Return Snapshot: The peer with the highest 1-year return is Parnax Lab, while Quest Laborato. has a 1-year return of -11.65%, which is lower than Bal Pharma's -2.12%. Additionally, Syschem (India) and Lactose (India) have negative six-month returns.

How big is Quest Laborato.?

As of 31st August, Quest Laboratories Ltd has a market capitalization of 144.00 Cr, with recent net sales of 111.81 Cr and a net profit of 15.02 Cr. Shareholder's funds are 81.80 Cr, and total assets are valued at 121.65 Cr as of March 2025.

As of 31st August, Quest Laboratories Ltd has a market capitalization of 144.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Quest Laboratories reported Net Sales of 111.81 Cr and a Net Profit of 15.02 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 81.80 Cr and Total Assets valued at 121.65 Cr.

Should I buy, sell or hold Quest Laboratories Ltd?

Are Quest Laboratories Ltd latest results good or bad?

Quest Laboratories Ltd's latest results show strong revenue growth of 68% year-on-year, reaching ₹25.62 crores, but a significant decline in net profit by 33.66% and a drop in operating margin to 13.23% indicate serious profitability concerns, suggesting the overall results are more negative than positive.

Quest Laboratories Ltd's latest results present a mixed picture. On one hand, the company achieved a notable revenue growth of 68.00% year-on-year, with net sales reaching ₹25.62 crores. This indicates strong market demand and effective expansion of its product portfolio. However, this impressive topline growth is overshadowed by significant profitability concerns. <BR><BR>Net profit for the quarter was ₹4.02 crores, which reflects a concerning decline of 33.66% compared to the same quarter last year. Additionally, the operating margin has sharply decreased to 13.23%, down from 32.15% a year ago, indicating that rising costs are eroding profitability despite increased sales. <BR><BR>The stock is currently trading below its key moving averages and has underperformed relative to its peers and the broader market, raising concerns about investor sentiment and future growth prospects. Overall, while the revenue growth is a positive sign, the decline in profitability and margins suggests that the results are more negative than positive, highlighting challenges that the company needs to address moving forward.

How has been the historical performance of Quest Laborato.?

Quest Laborato has shown significant growth from Mar'23 to Mar'25, with net sales increasing from 0.62 Cr to 103.91 Cr and profit after tax rising from 0.05 Cr to 13.57 Cr, despite a negative cash flow of -23.00 Cr in Mar'25. Total assets also grew from 46.94 Cr to 121.65 Cr during this period.

Answer:<BR>The historical performance of Quest Laborato shows significant growth in various financial metrics over the past few years.<BR><BR>Breakdown:<BR>Quest Laborato's net sales have increased from 0.62 Cr in Mar'23 to 103.91 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 0.62 Cr in Mar'23 to 103.91 Cr in Mar'25. The company's total expenditure, excluding depreciation, also rose from 0.53 Cr in Mar'23 to 87.93 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) grew from 0.09 Cr in Mar'23 to 20.22 Cr in Mar'25, showcasing improved profitability, while profit before tax increased from 0.07 Cr in Mar'23 to 18.68 Cr in Mar'25. Profit after tax also saw a substantial rise from 0.05 Cr in Mar'23 to 13.57 Cr in Mar'25. On the balance sheet, total assets grew from 46.94 Cr in Mar'23 to 121.65 Cr in Mar'25, with total liabilities increasing from 46.94 Cr to 30.26 Cr in the same period. The cash flow from operating activities turned negative at -23.00 Cr in Mar'25, contrasting with positive cash flows in previous years. Overall, Quest Laborato has demonstrated robust growth in revenue and profitability, despite challenges in cash flow management.

Is Quest Laborato. overvalued or undervalued?

As of September 16, 2025, Quest Laboratories is considered very attractive and undervalued with a PE ratio of 11.35 and strong financial metrics, despite a year-to-date stock decline of 21.27% compared to a 6.74% gain in the Sensex.

As of 16 September 2025, the valuation grade for Quest Laboratories has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, especially when considering its key financial ratios. The PE ratio stands at 11.35, while the EV to EBITDA is 8.47, and the ROCE is a strong 24.38%, showcasing efficient capital utilization.<BR><BR>In comparison to its peers, Quest Laboratories appears favorably positioned. For instance, Sun Pharma has a PE ratio of 33.64, categorizing it as expensive, while Cipla, deemed attractive, has a PE of 23.31. The PEG ratio for Quest is notably at 0.00, suggesting that it may be undervalued relative to its growth potential. Despite recent stock performance lagging behind the Sensex, with a year-to-date decline of 21.27% compared to a 6.74% gain in the index, the underlying financial metrics support a bullish outlook for Quest Laboratories.

What is the technical trend for Quest?

As of May 29, 2025, Quest's technical trend has shifted to bearish, supported by negative indicators from the MACD, Bollinger Bands, and moving averages, with no immediate reversal signals evident.

As of 29 May 2025, the technical trend for Quest has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. The weekly MACD is bearish, and the Bollinger Bands also reflect a bearish trend. Daily moving averages confirm the bearish outlook. The KST on a weekly basis is bearish as well. Overall, the lack of significant signals from the RSI, Dow Theory, and OBV suggests a continuation of the bearish trend without any immediate reversal signals.

Who are the top shareholders of the Quest?

The top shareholder of Quest is Anil Kumar Sabarwal, holding 62.29% of the shares, with individual investors owning 24.35% and three foreign institutional investors holding a combined 0.95%. The highest public shareholder is Priti Kamlesh Gandhi, who owns 1.22%.

The top shareholders of Quest include the promoters, with Anil Kumar Sabarwal holding the largest share at 62.29%. There are no pledged promoter holdings, and individual investors collectively hold 24.35% of the shares. Additionally, there are three foreign institutional investors (FIIs) that hold a combined 0.95%. The highest public shareholder is Priti Kamlesh Gandhi, who owns 1.22%.

When is the next results date for Quest?

No Upcoming Board Meetings

Has Quest declared dividend?

No Dividend History Available